Mapping the Functional Domains of BRCA1
INTERACTION OF THE RING FINGER DOMAINS OF BRCA1 AND BARD1*

Jose E. MezaDagger §, Peter S. Brzovicparallel **, Mary-Claire KingDagger , and Rachel E. Klevitparallel Dagger Dagger

From the Dagger  Departments of Genetics and Medical Genetics and the parallel  Department of Biochemistry and Biomolecular Structure Center, University of Washington, Seattle, Washington 98195-7742

    ABSTRACT
Top
Abstract
Introduction
References

Breast cancer 1 (BRCA1) and BRCA1-associated RING domain 1 (BARD1) are multidomain proteins that interact in vivo via their N-terminal RING finger motif regions. To characterize functional aspects of the BRCA1/BARD1 interaction, we have defined the structural domains required for the interaction, as well as their oligomerization state, relative stability, and possible nucleic acid binding activity. We have found that the RING finger motifs do not themselves constitute stable structural domains but are instead part of larger domains comprising residues 1-109 of BRCA1 and residues 26-119 of BARD1. These domains exist as homodimers and preferentially form a stable heterodimer. Shorter BRCA1 RING finger constructs do not interact with BARD1 or with longer BRCA1 constructs, indicating that the heterodimeric and homodimer interactions are mediated by regions outside the canonical RING finger motif. Nucleic acid binding is a generally proposed function of RING finger domains. We show that neither the homodimers nor the heterodimer displays affinity for nucleic acids, indicating that the proposed roles of BRCA1 and BARD1 in DNA repair and/or transcriptional activation must be mediated either by other regions of the proteins or by additional cofactors.

    INTRODUCTION
Top
Abstract
Introduction
References

Unraveling the cellular basis for BRCA1-mediated tumor suppression is a challenging goal that is complicated, in part, by the multifunctional nature of the protein. In large multifunctional proteins, such as BRCA1, different functions are often dispersed among discrete structural regions or domains. In such cases, functional studies can be facilitated by characterization of the properties of individual domains or subunits. Unfortunately, in the case of BRCA1, a large protein of 1863 amino acids, clues regarding the location or extent of independent functional domains are not readily available on the basis of sequence homologies. A noteworthy exception is the RING1 finger consensus motif located at the N-terminal end of the protein (1). The RING finger is a zinc-binding motif defined by a conserved pattern of cysteine and histidine residues that is found in a wide variety of proteins of diverse origin and function (2). Although more than 80 RING finger-containing proteins have been identified to date, a specific cellular function has not yet been associated with the motif (3). Nevertheless, the importance of the RING finger to BRCA1 function is supported by the following observations: 1) the first 100 residues, including the RING finger motif (residues 24-64), are the most highly conserved regions among known BRCA1 genes (4, 5); 2) several cancer-predisposing mutations have been identified within this region of BRCA1 (6, 7); and 3) yeast two-hybrid studies have identified two novel proteins that interact with this region of BRCA1 (8, 9).

One of the proteins found to associate with the BRCA1 N-terminal region, BARD1 (8), also contains an N-terminal RING finger motif (residues 50-86). Yeast two-hybrid studies showed that the N-terminal RING finger regions of both BRCA1 and BARD1 are required for specific heterocomplex formation between the proteins. Subsequent cellular localization studies demonstrated that BRCA1 and BARD1 localize to discrete nuclear foci (dots) during S phase and disperse during other phases of the cell cycle (10). In addition, complexes containing BRCA1 and BARD1 have been detected on damaged, replicating DNA structures (10). Taken together, these observations suggest that a multiprotein complex involving BRCA1 is responsive both to the cell cycle and to DNA damage and identify an important cellular interaction among the proteins.

Despite identification of heterologous protein interactions, the cellular basis of BRCA1-mediated tumor suppression remains elusive. When initially identified, it was suggested that the BRCA1 RING finger may play a role in specific DNA binding (1). Indeed, there has been considerable speculation regarding a general function for RING finger proteins in nucleic-acid interactions. To date, published data on the DNA binding properties of RING fingers are conflicting and equivocal: there are reports that particular RING finger proteins or domains bind synthetic oligonucleotides or DNA cellulose, whereas other reports provide evidence to the contrary (11-14). In no case, however, has specific nucleic acid binding been demonstrated. Nonetheless, BRCA1 has been reported associated with certain chromatin structures in vivo and linked to the RNA polymerase II holoenzyme complex (15, 16). These findings raise the possibility that BRCA1 might associate directly with nucleic acids either alone or upon formation of a complex with BARD1.

In order to characterize the functional significance of the BRCA1/BARD1 interaction further, we have sought to define the extent of the structural region encompassing the RING finger consensus motifs for both proteins. We find that the RING finger motifs do not themselves constitute stable structural units but are instead part of larger structural domains. Interactions and properties that may contribute to the function of these proteins, including their oligomerization states, relative stabilities, and nucleic acid binding activities are described herein.

    EXPERIMENTAL PROCEDURES

Materials-- 3,5-Dimethoxy-4-hydroxycinnamic acid (sinapinic acid) and 2,2':6',2"terpyridine were obtained from Aldrich and used without further purification. Limited proteolysis studies used sequencing grade endoproteinase Lys-C (Pierce) and V8 endo proteinase (Worthington). Bovine serum albumin, ovalbumin, alpha -chymotrypsinogen, and ribonuclease A, and glutaraldehyde were purchased from Sigma.

Preparation and Cloning of BRCA1 and BARD1 Constructs-- BC-76, BC-112, and BC-172 constructs were prepared as described previously (17). BARD1 constructs were prepared in a similar fashion using primers to obtain the desired BARD1 polymerase chain reaction products from human lymphoblast cDNA. The primers were synthesized with NheI and BamHI endonuclease restriction sites in the 5'- and 3'-ends, respectively. The polymerase chain reaction products and pET11a vector (Novagen) were then digested with NheI and BamHI, ligated, and transformed into Escherichia coli BL21 cells, and clones were sequenced as described previously for BRCA1 constructs (17). Because of the restriction sites used, each construct contains two extra amino acids (Ala and Ser) at the N terminus. BC-112 also contains two additional residues at its C terminus (Gly and Lys) as a result of the cloning procedure. Construct and fragment designations refer to the number and position of BRCA1 or BARD1 residues.

Expression and Purification of BRCA1 and BARD1 N-terminal Constructs-- BRCA1 constructs were expressed and purified as described previously (17). Purification of BARD1 constructs was identical to that of BRCA1 constructs with one minor modification. The BARD1-containing insoluble fraction was re-solubilized into 6 M guanidine-HCl as before (17), diluted to 2 M guanidine-HCl by dropwise addition of Tris buffer (50 mM Tris, 10 mM dithiothreitol, pH 7.6) and purified to homogeneity by reverse phase chromatography. Protein purity and concentration was determined as described previously for the BRCA1 constructs (17). Approximate extinction coefficients at 280 nm for BARD1 constructs, calculated on the basis of amino acid composition, are 19.55, 13.86, and 13.86 mM-1 cm-1 for BD 26-152, BD 26-140, and BD 26-131, respectively.

Fluorescence Spectroscopy-- Fluorescence spectra were measured on a Spex Fluorolog 2 fluorometer using a 1 × 0.5-cm cuvette at 25 °C. BARD1 homodimer and BRCA1/BARD1 heterodimer sample (1.0 ml) concentrations were adjusted to 1 µM BARD1 monomer in 25 mM Tris, 200 mM NaCl buffer at pH 7.6. Spectra were collected using an excitation wavelength of 290 nm and scanning the emission spectrum between 300 and 450 nm.

Stoichiometry Determination and Limited Proteolysis-- Gel-filtration chromatography, glutaraldehyde cross-linking, limited proteolysis, and MALDI-TOF spectroscopy experiments were performed as described previously (17).

Nucleic Acid Binding-- BRCA1, BARD1, and the ADR1 zinc finger domain constructs were purified by gel-filtration chromatography in 25 mM Tris, 50 mM NaCl, pH 7.6 (Buffer 1). Peak fractions (approximately 10 µM by absorbance) were loaded onto double- and single-stranded DNA cellulose (calf thymus DNA, Sigma) and synthetic RNA (poly(A), poly(C), poly(G), and poly(U)) agarose (Sigma) columns at a flow rate of 0.2 ml/min in Buffer 1. Columns were washed with 5 column volumes of Buffer 1 to remove nonspecifically bound material. The bound material was eluted with a 50-350 mM NaCl gradient (5 column volumes), followed by a 350-600 mM NaCl gradient (2 column volumes), and a final wash with 2 M NaCl to remove tightly bound protein. Each column (Perseptive Biosystems) was packed with approximately 1 ml of nucleic acid resin. The identity of eluted material was verified by analysis of peak fractions on 14% SDS-PAGE.

    RESULTS

The BRCA1 RING Finger Structural Domain Extends beyond the RING Finger Homology Region-- Three different sized BRCA1 RING finger constructs (termed BC-76, BC-112, and BC-172; Table I) were tested for their ability to interact with a BARD1 RING finger construct. The BARD1 construct (BD 26-152) encompasses residues 26-152 and was chosen on the basis of reported two-hybrid studies (8).2 We used gel-filtration chromatography to assess the oligomeric states of the constructs. Fig. 1A illustrates gel-filtration elution profiles for BC-172, BD 26-152, and a 1:1 mixture of the two constructs. Individually, each construct elutes primarily as a single peak at an elution volume that corresponds to a molecular weight roughly twice the expected value, suggesting that both BC-172 and BD 26-152 homodimerize in solution. An equimolar mixture of the two constructs elutes as a single sharp peak with a width comparable to those of standard proteins used for column calibration. The intermediate elution volume relative to the two individual species is indicative of a heterodimeric complex between BC-172 and BD 26-152. Similar results were obtained with BC-112 and BD 26-152 (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Description of BRCA1 and BARD1 N-terminal constructs
Residues encompassed by each construct, corresponding calculated molecular masses, and masses determined by MALDI-TOF mass spectrometry are shown.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of the oligomeric states of BRCA1 and BARD1 N-terminal constructs. A, analytical gel-filtration elution profiles for BC-172 (dotted trace), BD 26-152 (solid trace), and an equimolar mixture of BC-172/BD 26-152 (dashed trace). Positions for the protein standards bovine serum albumin (66 kDa), ovalbumin (43 kDa), alpha -chymotrypsinogen (23 kDa), and RNase (13.7 kDa) are indicated by arrows. B, SDS-PAGE of glutaraldehyde cross-linking reactions of BC-172 homodimer (lanes 1 and 2), BC-172/BD 26-152 heterodimer (lanes 3 and 4), and BD 26-152 homodimer (lanes 5 and 6) complexes. Molecular mass standards are shown in lane 7. Each complex was incubated for 5 min in the presence (lanes 1, 3, and 5) or absence (lanes 2, 4, and 6) of 0.01% (v/v) glutaraldehyde. The position of molecular mass markers (right) and the monomeric (M), homodimeric (D), and heterodimeric (H) complexes are indicated (left). C, analytical gel-filtration chromatography of BC-76 (solid trace) and an equimolar mixture of BC-76 and BC-172 (dashed trace) RING finger domain constructs. The mixture elutes as two separate peaks from the gel-filtration column at volumes corresponding to the expected molecular weights of BC-76 and BC-172 homodimers, demonstrating that the two constructs do not interact.

Glutaraldehyde cross-linking of peak fractions collected from gel-filtration columns, followed by SDS-PAGE, confirmed the oligomerization state of each species. Fig. 1B shows results of cross-linking experiments performed on the BC-172, BC-172/BD 26-152, and BD 26-152 peak fractions. Each cross-linking reaction produced a new band not present in the starting material (Fig. 1B, compare lanes 1, 3, and 5 with lanes 2, 4, and 6, respectively). The cross-linked bands in lanes 1 and 5 run at molecular masses that correspond to the homodimeric form of BC-172 and BD 26-152 (~40 kDa and ~29 kDa, respectively), whereas the cross-linked band in lane 3 exhibits an intermediate molecular mass, which corresponds to that of the BC-172/BD 26-152 heterodimer (~34.5 kDa). Similar to the results from the gel-filtration analysis, the cross-linking experiments demonstrate that the heterodimer is formed preferentially relative to the homodimeric species in solution. Again, similar cross-linking results were obtained with BC-112 and BD 26-152 (data not shown).

BD 26-152 contains three tryptophans, whereas BC-112 contains no tryptophans (see Fig. 6 for sequences), allowing the use of fluorescence to distinguish the BD 26-152 homodimer from the BC-112/BD 26-152 heterodimer. The fluorescence spectrum of the BD 26-152 homodimer exhibits an emission maximum at 347 nm (lambda ex = 290 nm). The emission maximum of an equimolar mixture of BC-112 and BD 26-152 is blue-shifted to 335 nm with a corresponding increase in intensity (Fig. 2). Under the conditions used in the fluorescence experiments, BD 26-152 is a homodimer. Therefore, the shift and increase in emission intensity indicate that at least one tryptophan in BD 26-152 experiences a more hydrophobic environment in the heterodimer relative to the homodimer. The fluorescence spectrum of the heterodimer isolated by gel-filtration is virtually identical to the spectrum obtained by direct mixing of the proteins (data not shown).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Change in BARD1 tryptophan fluorescence upon heterodimer formation. Tryptophan fluorescence emission spectra (lambda ex = 290 nm) of BD 26-152 homodimer (solid trace) and an equimolar mixture of BC-112 and BD 26-152 (dashed trace) are shown. The BD 26-152 homodimer exhibits an emission maximum at 347 nm, whereas the emission maximum of the BC-112/BD 26-152 heterodimer blue-shifts to 335 nm with a concomitant increase in fluorescence intensity.

We have previously demonstrated that the short BRCA1 construct, BC-76, forms a homodimer (17). However, using the approaches described above, we do not detect heterodimer formation with BC-76 and BD 26-152 (data not shown). Furthermore, mixtures of BC-76 and BC-172 elute as two separate peaks from the gel-filtration column at volumes corresponding to the expected molecular weights of BC-76 and BC-172 homodimers (Fig. 1C). Similar results were obtained with mixtures of BC-76 and BC-112 (data not shown). Thus, the BC-76 RING finger construct does not dimerize with either BC-112, BC-172, or BD 26-152, indicating that specific and high affinity BRCA1 homodimerization and heterodimerization with BARD1 requires BRCA1 residues C-terminal to position 76.

Determination of the Structural BRCA1 and BARD1 Domains Required for Heterodimerization-- To identify the structural domains of BRCA1 and BARD1 required for heterodimerization, we used limited proteolysis in conjunction with matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. The premise behind this experimental approach is that regions of proteins that are structured are less susceptible to proteolysis than regions of proteins that are flexible or disordered. This approach has also been used to map regions of proteins involved in mediating interactions with other molecules (18).

The BC-112/BD 26-152 heterodimer was probed with endoprotease Endo Lys C, which cleaves on the C-terminal side of lysine residues. Fig. 3 shows MALDI-TOF mass spectra that were collected at various times after the addition of protease. Although there are potential cleavage sites throughout the primary sequence of both BC-112 and BD 26-152 (see Fig. 6), cleavage only occurs in a limited number of sites. Twenty-five minutes after the addition of protease, BC-112 is cleaved mainly at Lys109, generating fragment BC 1-109 (Fig. 3B). BC 1-109 is quite resistant to further proteolysis, persisting even 60 min into the reaction (Fig. 3C). Cleavage also occurs at Lys55 of BC-112, generating fragments 1-55 and 56-109, which are also resistant to further proteolysis. Our previous studies showed that this same site is also accessible in the BC-112 homodimer (17). BD 26-152 quickly loses 22 residues from its C terminus, generating a BD 26-130 fragment (Fig. 3B), which is very stable: no additional cleavage occurs within the fragment even after 60 min of proteolysis (Fig. 3C).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Determination of BRCA1 and BARD1 N-terminal structural domains. MALDI-TOF mass spectra for the limited proteolytic digest of the BC-112/BD 26-152 heterodimer with Endo Lys C are shown. Samples were collected before the addition of protease (A) and 25 (B) and 60 (C) min after the addition of protease. Peaks labeled +2 indicate doubly protonated fragments that arise from the MALDI process. Peaks corresponding to singly charged fragments are labeled with residue numbers as determined from the measured mass.

Limited proteolysis was also performed with V8, which cleaves on the C-terminal side of glutamate residues (see Fig. 6 for sequences). Sixty minutes after the addition of protease, BC-112 remained intact, whereas BARD1 was cleaved at residue 119, generating a stable BD 26-119 fragment (see Fig. 5B). Taken together, these results show that BRCA1 and BARD1 RING finger motifs are part of larger structural domains, comprising the first 109 residues of BRCA1 and residues 26-119 of BARD1.

Differences in Proteolytic Susceptibility between Homodimeric and Heterodimeric Complexes-- Proteolytic susceptibilities of the homodimers and the heterodimer were compared to probe for distinguishing features among the species. Two shorter BARD1 constructs, BD 26-131 and BD 26-140 (Table I), engineered based on the proteolysis results reported above, were used with BC-112 in these experiments. As illustrated in Fig. 4, the mass spectra of Endo Lys C reactions of the two homodimers and the heterodimer show striking differences. Twenty-five minutes after digestion, the only species of BD 26-140 observed in the heterodimer reaction was the large BD 26-130 fragment (Fig. 4B). In contrast, cleavage occurred at virtually every lysine in the BD 26-140 homodimer reaction (Fig. 4C).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of proteolytic susceptibility of BRCA1 and BARD1 homodimers and heterodimer. MALDI-TOF mass spectra for the limited proteolytic digest of BC-112 (A), BC-112/BD 26-140 (B), and BD 26-140 (C) complexes with Endo Lys C. Spectra shown are of samples collected 25 min after the addition of protease.

The differences in susceptibility of BC-112 in the homodimer versus heterodimer are less striking than those of BD 26-140. Most of the same cleavages occur (Fig. 4, A and B) in the two forms, with one clear exception: cleavage occurs at an N-terminal lysine, Lys20, in the homodimer, but not in the heterodimer. Thus, the N-terminal region of BC-112 becomes protected upon dimerizing with BD 26-140.

To further probe differences in the N-terminal region of BRCA1, limited proteolysis was performed with V8. The mass spectra shown in Fig. 5 illustrate a pronounced difference in the proteolytic susceptibility between the BRCA1 homodimer and heterodimer to V8. The enzyme readily cleaved the N-terminal region of the homodimer, generating fragments BC 11-112, BC 11-100, and BC 11-75 (Fig. 5A). In contrast, BC-112 remained completely intact in the heterodimer (Fig. 5B). Taken together, the proteolysis results, summarized in Fig. 6, clearly illustrate that in each case the homodimers are more susceptible to proteolysis than the heterodimer. Similar results were observed with the slightly shorter BD 26-131 construct (data not shown).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Comparison of susceptibility of BRCA1 homo- and heterodimer complexes to V8 proteolysis. MALDI-TOF mass spectra of BC-112 homodimer (A) and BC-112/BD 26-140 heterodimer (B) complex samples collected 60 min after the addition of V8 protease. The asterisk denotes the presence of known sample impurities.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   Summary of limited proteolysis results. BC-112 and BD 26-152 constructs are aligned according to their conserved residues. RING finger motif conserved residues are underlined and boldface. Arrowheads above and below each sequence indicate susceptible cleavage sites in homodimeric (small arrowheads) and heterodimeric (large arrowheads) complexes. The superscript number on the first and last conserved RING finger cysteine residues in each motif corresponds to the amino acid number in the sequence of each protein. Tryptophan residues are shown in green, and potential Endo Lys C and V8 cleavage sites are shown in blue and red, respectively.

Neither Homodimeric nor the Heterodimeric Complex Binds Nucleic Acids-- We tested the ability of our RING finger constructs to bind nucleic acids using double- and single-stranded DNA cellulose and single-stranded RNA agarose (poly(A), poly(C), poly(G), and poly(U)) columns. Homodimeric (BC-112, BD 26-131, and BD 26-140) and heterodimeric (BC-112/BD 26-131 and BC-112/BD 26-140) complexes were applied to each nucleic acid column and eluted with a NaCl gradient. The zinc finger domain from ADR1 (a known DNA-binding domain from a yeast transcription factor) was used as a positive control (19). Fig. 7 shows the elution profiles for BC-112, BD 26-140, BC-112/BD 26-140, and the ADR1 zinc finger domain from a double-stranded DNA column. Whereas the ADR1 zinc finger was retained on the column, eluting at ~400 mM NaCl, the RING finger complexes showed no affinity for double-stranded DNA, eluting in the void volume (50 mM NaCl). A general property of nucleic acid-binding proteins is that they exhibit detectable affinity to nonspecific nucleic acids. The sequence-specific DNA-binding ADR1 zinc finger domain displays this property. ADR1 bound to every column assayed, eluting from single-stranded DNA, poly(A), poly(C), poly(G), and poly(U) RNA columns at NaCl concentrations of ~350, ~325, ~200, ~400, and ~150 mM, respectively. In direct contrast, neither homodimer nor the heterodimer displayed any affinity for the columns tested, with the protein eluting in the 50 mM NaCl wash in every case (data not shown). Similar results are observed with the BD 26-131 construct (data not shown).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 7.   BRCA1 and BARD1 N-terminal complexes do not bind nucleic acids. Elution profiles of the BC-112 homodimer (dotted trace), BD 26-140 homodimer (solid trace), BC-112/BD 26-140 heterodimer (dashed trace), and the ADR1 zinc finger domain (solid trace) from the double-stranded DNA-cellulose column are shown. Samples were applied in equilibration buffer containing 50 mM NaCl. Every RING finger species tested failed to bind, eluting in the void volume, whereas the ADR1 zinc finger domain (a known DNA-binding domain) was retained by the DNA column and eluted at [NaCl] ~400 mM. The arrowheads below the elution profiles indicate the NaCl concentration gradient used.


    DISCUSSION

Although BRCA1 has been implicated in the maintenance of genome integrity (10, 15) and in transcriptional activation (16, 20), little is known about its specific function in either of these processes. In an approach aimed at characterizing functional properties of BRCA1, we have focused on its interactions with BARD1, a protein shown to interact with BRCA1 in vivo (8). Our results demonstrate that, individually, BRCA1 and BARD1 RING finger constructs exist as homodimers and that they preferentially form heterodimers. Limited proteolysis analysis defines the RING finger structural domains required for heterodimerization as comprising residues 1-109 of BRCA1 and residues 26-119 of BARD1. The heterodimer is remarkably stable, existing at concentrations well below 10-7 M.3

The RING finger motifs correspond to residues 24-64 and residues 50-86 in BRCA1 and BARD1, respectively. Thus, our results demonstrate that these motifs are part of a larger structural domain, rather than representing stable autonomous domains themselves. A similar situation exists for the recombination-activating gene 1 (RAG1) protein, the RING finger motif of which is also contained within a larger domain that exists as a homodimer in solution (21). The three domains share little homology aside from the consensus RING finger motif residues, and RAG1 does not share additional sequence homology with either BRCA1 or BARD1.

There are several reports of studies in which constructs that consist of a minimal RING finger motif sequence have been characterized, including a metal binding study of the RING finger (residues 22-77) of BRCA1 (22) and solution structure studies of the RING fingers from promyelocytic leukemia proto-oncoprotein and immediate-early equine herpesvirus-1 protein (11, 23). In contrast to BRCA1, BARD1, and RAG1, the short RING finger constructs used in the structure determinations were reported to be monomeric. In each case, however, the authors observed low solubility and a tendency of the constructs to aggregate. This is consistent with our experience with shorter RING finger constructs of BRCA1.4 Although results derived from studies involving minimal RING finger constructs may provide interesting information, the use of suboptimal domains may not reflect properties of the native proteins. In contrast, longer constructs of BRCA1 and BARD1 have good solubility properties and are well behaved in solution, which are general properties of stable, folded structural domains.

Our studies and others (8, 9) demonstrate that the N-terminal domain of BRCA1 is capable of high affinity protein-protein interactions with heterologous partners. There has been much speculation in the literature, however, concerning the role of RING finger domains as potential DNA-binding modules (3). The conflicting reports on the DNA binding ability of RING finger domains, along with studies that implicate BRCA1 and BARD1 in DNA repair and transcriptional activation, led us to test the nucleic acid binding properties of our well behaved and well characterized RING finger constructs. Despite the fact that all the constructs are positively charged at neutral pH, with calculated pI values ranging from 7.7 to 8.4, neither homodimer nor the heterodimer exhibited any nucleic acid binding activity. Consequently, if BRCA1 and BARD1 play a role in DNA repair and/or transcriptional activation, interactions with DNA must be mediated either by other regions of the proteins or by additional cofactors.

Proteolysis mapping and fluorescence experiments provide general structural insights as a preliminary step toward building a picture of the BRCA1/BARD1 heterodimer. The strong protection from proteolysis of regions outside the RING finger motif afforded in the heterodimer suggests that these regions may play a direct role in the heterodimer interface. In contrast, Lys55, a residue within the BRCA1 RING finger motif, is susceptible to proteolysis both in the homodimer and the heterodimer, suggesting that it is surface-accessible in both forms. Therefore, the loop that contains Lys55, which is highly variable both in sequence and structure among known RING fingers, does not appear to play a direct role in heterodimer formation and may be accessible for interactions with other molecules. The significant blue shift and intensity enhancement of intrinsic tryptophan (Trp) fluorescence observed upon heterodimer formation indicates that at least one of the three BD 26-152 Trp residues becomes buried. Of the three Trp residues in BD 26-152 (see Fig. 6), Trp146 is very near the C-terminal end of the construct and is readily removed by proteases in the heterodimer, making it unlikely that Trp146 is responsible for the observed fluorescence change. The two other Trp residues (Trp34 and Trp91) flank the RING finger motif and are close to sites that become protected to proteolysis in the heterodimer, suggesting that one or both of these Trps undergo a change in environment.

Results from gel-filtration (Fig. 1A), cross-linking (Fig. 1B), and fluorescence (Fig. 2) studies convincingly show that the heterodimer is the preferred species in solution. Additionally, limited proteolysis results indicate that homodimers are consistently more susceptible to proteolysis than the heterodimer. BD 26-140 is cleaved by Endo Lys C at virtually every lysine residue in the homodimer, whereas cleavage occurs only at Lys130 in the heterodimer (Fig. 6). Likewise, BC-112 is susceptible to proteolysis at its N-terminal region in its homodimeric state, whereas the same region is protected in its heterodimeric state (Fig. 6). The added proteolytic protection afforded to the heterodimer is in good agreement with the observation that it is the preferred species in solution and suggests that it is a functionally relevant species in the cell.

A major challenge in the study of breast cancer and other diseases is the determination of the functions of the proteins involved. An important early step in such efforts is the identification of structural domains and binding partners. Such a characterization can greatly aid in biochemical and functional studies of large multidomain, multifunctional proteins. The studies reported here are a first step in our goal to identify and understand the structure and function of the N-terminal regions of BRCA1 and BARD1.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants RO1 GM46701 and RO1 CA79953 (to R. E. K.) and RO1 CA27632 (to M.-C. K.) and a generous contribution from the Boeing Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by a Research Supplement for Underrepresented Minorities from the National Institutes of Health (RO1 CA27632-18S1).

These authors contributed equally to this work.

** Supported in part by an American Cancer Society postdoctoral fellowship.

Dagger Dagger To whom correspondence should be addressed: Dept. of Biochemistry and Biomolecular Structure Center, Univ. of Washington, Box 357742, Seattle, WA 98195-7742. Fax: 206-543-8394; E-mail: klevit{at}u.washington.edu.

2 BARD1 contains two potential initiator methionines (residues Met1 and Met26). The yeast two-hybrid studies showed that the first 25 residues of BARD1 are not required for the BRCA1/BARD1 interaction.

3 Serial dilution experiments failed to detect dissociation of the dimers by either fluorescence or gel-filtration to the lowest concentrations at which a signal could be measured (J. Meza, P. Brzovic, and R. Klevit, unpublished observation).

4 J. Meza, P. Brzovic, and R. Klevit, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: RING, really interesting new gene; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; Endo, endoproteinase.

    REFERENCES
Top
Abstract
Introduction
References
  1. Miki, Y., Swensen, J., Shattuch-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., and Liu, Q. (1994) Science 266, 66-71[Medline] [Order article via Infotrieve]
  2. Freemont, P. S. (1993) Ann. N. Y. Acad. Sci. 684, 174-192[Medline] [Order article via Infotrieve]
  3. Saurin, A. J., Borden, K. L. B., Boddy, M. N., and Freemont, P. S. (1996) Trends Biochem. Sci. 21, 208-214[CrossRef][Medline] [Order article via Infotrieve]
  4. Sharan, S. K., Wims, M., and Bradley, A. (1995) Hum. Mol. Genet. 4, 2275-2278[Abstract]
  5. Abel, K. J., Xu, J., Yin, G.-Y., Lyons, R. H., Meisler, M. H., and Weber, B. L. (1995) Hum. Mol. Genet. 4, 2265-2273[Abstract]
  6. Castilla, L. H., Couch, F. J., Erdos, M. R., Hoskins, K. F., Calzone, K., Garber, J. E., Boyd, J., Lubin, M. B., Deshano, M. L., Brody, L. C., Collins, F. S., and Weber, B. L. (1994) Nat. Genet. 8, 387-391[Medline] [Order article via Infotrieve]
  7. Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., and King, M.-C. (1994) Nat. Genet. 8, 399-404[Medline] [Order article via Infotrieve]
  8. Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., Yang, M.-C. W., Hwang, L.-Y., Bowcock, A. M., and Baer, R. (1996) Nat. Genet. 14, 430-440[Medline] [Order article via Infotrieve]
  9. Jensen, D. E., Proctor, M., Marquis, S. T., Gardner, H. P., Ha, S. I., Chodosh, L. A., Ishov, A. M., Tommerup, N., Vissing, H., Sekido, Y., Borodovsky, A., Schultz, D. C., Wilkinson, K. D., Maul, G. G., Barlev, N., Berger, S. L., Prendergast, G. C., and Rauscher, F. J. I. (1998) Oncogene 16, 1097-1112[CrossRef][Medline] [Order article via Infotrieve]
  10. Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D. M. (1997) Cell 90, 425-435[Medline] [Order article via Infotrieve]
  11. Barlow, P. N., Luisi, B., Milner, A., Elliot, M., and Everett, R. (1994) J. Mol. Biol. 237, 201-211[CrossRef][Medline] [Order article via Infotrieve]
  12. Everett, R. D., Barlow, P., Milner, A., Luisi, B., Orr, A., Hope, G., and Lyon, D. (1993) J. Mol. Biol. 234, 1038-1047[CrossRef][Medline] [Order article via Infotrieve]
  13. Lovering, R., Hanson, I. M., Borden, K. L. B., Martin, S., O'Reilly, N. J., Evan, G. I., Rahman, D., Pappin, D. J. C., Trowsdate, J., and Freemont, P. S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2112-2116[Abstract]
  14. Tagawa, M., Sakamoto, T., Shigemoto, K., Matsubara, H., Tamura, Y., Ito, T., Nakamura, I., Okitsu, A., Imai, K., and Taniguchi, M. (1990) J. Biol. Chem. 265, 20021-20026[Abstract/Free Full Text]
  15. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D. M. (1997) Cell 88, 265-275[Medline] [Order article via Infotrieve]
  16. Scully, R., Anderson, S. F., Chao, D. M., Wei, W., Ye, L., Young, R. A., Livingston, D. M., and Parvin, J. D. (1997) Proc. Natl. Acad. Sci., U. S. A. 94, 5605-5610[Abstract/Free Full Text]
  17. Brzovic, P. S., Meza, J., King, M.-C., and Klevit, R. E. (1998) J. Biol. Chem. 273, 7795-7799[Abstract/Free Full Text]
  18. Cohen, S. L., Ferre-D'Amare, A. R., Burley, S. K., and Chait, B. T. (1995) Protein Sci. 4, 1088-1099[Abstract/Free Full Text]
  19. Shuster, J., Yu, J., Cox, D., Chan, R. V. L., Smith, M., and Young, E. T. (1986) Mol. Cell. Biol. 6, 1894-1902[Medline] [Order article via Infotrieve]
  20. Chapman, M. S., and Verma, I. M. (1996) Science 382, 678-679
  21. Bellon, S. F., Rodgers, K. K., Schatz, D. G., Coleman, J. E., and Steitz, T. A. (1997) Nat. Struct. Biol. 4, 586-591[Medline] [Order article via Infotrieve]
  22. Roehm, P. C., and Berg, J. (1997) Biochemistry 36, 10240-10245[CrossRef][Medline] [Order article via Infotrieve]
  23. Borden, K. L. B., Boddy, M. N., Lally, J., O'Reilly, N. J., Martin, S., Howe, K., Solomon, E., and Freemont, P. S. (1995) EMBO J. 14, 1532-1541[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.